Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $809.6352W HIGH $1,321.21
Volume
2.11 M
Value Traded
3.68 B
Short % Float
0.83%
Days to Cover
2.9
-0.35%Week
+7.96%1 Month
+4.79%3 Month
+46.35%6 Month
+432.5%5 Year
+37,819.33%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
1204.13 B
EPS (TTM)
29.97
P/E Ratio
42.69
Ent. Value
1243.04 B
Total Shares
940.94 M
Float Shares
848.41 M
Insiders
9.87%
Institutions
76.46%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LLY Catalyst Timeline
Dated clinical, regulatory and corporate events for Eli Lilly and Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eli Lilly and Company
2713Total events
63Upcoming
1129Tier-1 (high impact)
2011 to 2040Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationOlomorasibPresentation
Rapid oral presentation of olomorasib plus chemoimmunotherapy first-line NSCLC data at ESMO 2026
first-line advanced KRAS G12C-mutant NSCLCsource ↗
▲Poster PresentationOlomorasibPresentation
Poster presentation of olomorasib plus pembrolizumab first-line NSCLC data at ESMO 2026
first-line KRAS G12C-mutant non-small cell lung cancersource ↗
▲Oral Presentationsofetabart mipitecanPresentation
Phase 1 Sofe-M plus bevacizumab data presented orally at ESMO 2026
platinum-sensitive ovarian cancersource ↗
▲Topline Readoutsofetabart mipitecanClinical Data
Phase 1 Sofe-M plus bevacizumab shows 79.3% cORR and 100% DCR in PSOC
platinum-sensitive ovarian cancersource ↗
▲Manufacturing MilestoneCMC / Inspection
Lilly breaks ground on $5B Richmond, Virginia manufacturing facility for ADCs and large-molecule medicines
▲Primary Endpoint MetMirikizumabApprovedClinical Data
Omvoh meets primary endpoint of clinical remission at Week 52 in pediatric UC (SHINE-2)
pediatric ulcerative colitissource ↗
●Safety Data UpdateMirikizumabApprovedClinical Data
SHINE-2 safety profile through Week 52 consistent with adults, no new signals
pediatric ulcerative colitissource ↗
▲Late-BreakerMirikizumabApprovedPresentation
SHINE-2 one-year results presented as late-breaking oral presentation at UEG Week 2026
pediatric ulcerative colitissource ↗
▲Full ResultsMirikizumabApprovedClinical Data
One-year Phase 3 SHINE-2 results in pediatric UC reported
pediatric ulcerative colitissource ↗
▲Additional DataMirikizumabApprovedClinical Data
Post hoc analysis of corticosteroid-free deep remission at one year in VIVID-1
Crohn's diseasesource ↗
▲Poster PresentationMirikizumabApprovedPresentation
Post-hoc VIVID-1 corticosteroid-free deep remission analysis presented at UEG Week 2026
Crohn's diseasesource ↗
▲Additional DataMirikizumabApprovedClinical Data
27.7% of Omvoh patients achieved comprehensive disease control vs 14% placebo at one year
ulcerative colitissource ↗
▲Full ResultsMirikizumabApprovedClinical Data
Comprehensive disease control achieved in 27.7% of Omvoh patients vs 14% placebo at one year
ulcerative colitissource ↗
▲Late-BreakerMirikizumabApprovedPresentation
SHINE-2 Week 12 results presented as late-breaking oral presentation at ACG 2026 Annual Scientific Meeting
pediatric ulcerative colitissource ↗
▲Poster PresentationMirikizumabApprovedPresentation
Post-hoc LUCENT comprehensive disease control analysis presented at ACG 2026
ulcerative colitissource ↗
▲Additional DataMirikizumabApprovedClinical Data
Post hoc analysis of comprehensive disease control at one year in LUCENT-2
ulcerative colitissource ↗
▲Additional DataZepboundApprovedClinical Data
Exploratory biomarker data from TOGETHER-PsO presented at Fall Clinical 2026
moderate-to-severe plaque psoriasis and obesity or overweightsource ↗
▲Additional DataIxekizumabApprovedClinical Data
Exploratory biomarker data from TOGETHER-PsO presented at Fall Clinical 2026
moderate-to-severe plaque psoriasis and obesity or overweightsource ↗
▲Oral PresentationPresentation
TOGETHER-PsO exploratory data presented at 2026 Fall Clinical Dermatology Conference
moderate-to-severe plaque psoriasis and obesity or overweightsource ↗
▲Biomarker DataIxekizumabApprovedClinical Data
Exploratory biomarker data from TOGETHER-PsO presented at Fall Clinical 2026
moderate-to-severe plaque psoriasis and obesity or overweightsource ↗
▲Biomarker DataZepboundApprovedClinical Data
Exploratory biomarker data from TOGETHER-PsO presented at Fall Clinical 2026
moderate-to-severe plaque psoriasis and obesity or overweightsource ↗
◆Poster PresentationLebrikizumabApprovedPresentation
Lebrikizumab impact on alleviating disease severity, itch burden and quality of life in patients with moderate-to-severe atopic dermatitis: 16-week interim results from a European prospective observational study (ADtrust)
moderate-to-severe atopic dermatitissource ↗
◆Poster PresentationEloralintideApprovedPresentation
Concomitant treatment with ixekizumab and tirzepatide according to demographics and disease characteristics for patients with psoriasis and overweight or obesity: Subgroup analyses from the TOGETHER-PsO randomized trial
psoriasis and overweight or obesitysource ↗
◆Poster PresentationBaricitinibApprovedPresentation
Baricitinib provides sustained efficacy through 1.5 years and consistent safety up to a maximum of 2.5 years of treatment in adolescents with severe alopecia areata: BRAVE-AA-PEDS trial results
severe alopecia areatasource ↗
◆Poster PresentationIxekizumabApprovedPresentation
Ixekizumab plus tirzepatide reduced CV risk factors vs ixekizumab alone
psoriatic disease and obesitysource ↗
▲FDA ApprovalPirtobrutinibApprovedFDA Decision
FDA approves expanded indication for Jaypirca in previously untreated CLL/SLL
previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletionsource ↗
▲Full ResultsOrforglipronApprovedClinical Data
Post-hoc analyses of ATTAIN-1 published showing reductions in predicted 10-year type 2 diabetes and cardiovascular disease risk
Obesity or overweight with a weight-related medical problemsource ↗
▲PublicationOrforglipronApprovedPresentation
Post-hoc analyses of ATTAIN-1 published in Diabetes, Obesity and Metabolism
Obesity or overweight with a weight-related medical problemsource ↗
▲Primary Endpoint MetEBGLYSSApprovedClinical Data
ADtouch primary endpoint met: 53% vs 27% placebo achieved HF-IGA 0/1 at Week 16
moderate-to-severe hand and foot atopic dermatitissource ↗
◆Late-BreakerEBGLYSSApprovedPresentation
ADtouch late-breaking results to be presented at EADV Congress
moderate-to-severe hand and foot atopic dermatitissource ↗
▲Topline ReadoutEBGLYSSApprovedClinical Data
EBGLYSS Phase 3b ADtouch topline results announced
moderate-to-severe hand and foot atopic dermatitissource ↗
▲Topline ReadoutEloraTZPClinical Data
Lilly announced positive Phase 2b results for EloraTZP in obesity/overweight with type 2 diabetes
obesity or overweight and type 2 diabetessource ↗
▲Primary Endpoint MetEloraTZPClinical Data
EloraTZP met primary endpoint of percent change in body weight vs placebo at 48 weeks
obesity or overweight and type 2 diabetessource ↗
▲Oral PresentationEloraTZPPresentation
Phase 2b EloraTZP results presented at the 62nd Annual Meeting of EASD in Milan, Italy
obesity or overweight and type 2 diabetessource ↗
◆Oral PresentationEBGLYSSApprovedPresentation
Almirall to present five-year ADlong results at EADV
moderate-to-severe atopic dermatitissource ↗
▲Topline ReadoutOrforglipronApprovedClinical Data
Lilly announced detailed Phase 3 ACHIEVE-4 results for Foundayo (orforglipron) vs insulin glargine
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲Primary Endpoint MetOrforglipronApprovedClinical Data
ACHIEVE-4 met primary objective of non-inferiority for MACE-4 vs insulin glargine
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲Oral PresentationOrforglipronApprovedPresentation
ACHIEVE-4 results presented at 62nd Annual Meeting of EASD in Milan, Italy
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲PublicationOrforglipronApprovedPresentation
ACHIEVE-4 results simultaneously published in The Lancet
type 2 diabetes with obesity or overweight at increased cardiovascular risksource ↗
▲FDA ApprovalOnswikApprovedFDA Decision
FDA approves Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes
type 2 diabetessource ↗
▲Grant / FundingCorporate
$12.5 million support to San Jacinto College for manufacturing talent pipeline
▲Manufacturing MilestoneOrforglipronApprovedCMC / Inspection
Lilly breaks ground on $6.5B Houston API manufacturing site
◆Poster PresentationOrforglipronApprovedPresentation
ATTAIN-1 Physical and Psychosocial Functioning data for Foundayo presented at EASD 2026
obesity or overweight with at least one weight-related medical problemsource ↗
◆Poster PresentationZepboundApprovedPresentation
SURMOUNT-5 Exploratory Proteomic Findings for Zepbound presented at EASD 2026
obesity or overweightsource ↗
◆Poster PresentationMounjaroApprovedPresentation
SURPASS-EARLY Pre-Specified Analysis for Mounjaro presented at EASD 2026
early type 2 diabetessource ↗
◆Poster PresentationEloraTZPPresentation
EloraTZP Phase 1 results presented at EASD 2026
obesity or overweightsource ↗
◆Oral PresentationOrforglipronApprovedPresentation
Foundayo ACHIEVE-2/ACHIEVE-3 time-to-goal analysis presented at EASD 2026
type 2 diabetessource ↗
▲Oral PresentationEloraTZPPresentation
Phase 2b EloraTZP results presented at the 62nd Annual Meeting of EASD in Milan, Italy
obesity or overweight and type 2 diabetessource ↗
▲Full ResultsIxekizumabApprovedClinical Data
52-week results from TOGETHER-PsO announced
psoriatic disease and obesitysource ↗
Past FDA Catalysts and PDUFA Decisions
How LLY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-26 | selpercatinib (Retevmo) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
126
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 1 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Mounjaro | |||
| Zepbound | |||
| Verzenio | |||
| Trulicity | |||
| Jardiance | |||
| Taltz |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Orforglipron Small moleculeNCT07153471 | Osteoarthritis | Phase 3 | ACTIVE NOT_RECRUITING | 800 | May 1, 2028 | ||||||
| Baricitinib Small moleculeNCT04088396 | Systemic Juvenile Idiopathic Arthritis | Phase 3 | ACTIVE NOT_RECRUITING | 58 | Oct 1, 2026 | ||||||
| Orforglipron Small moleculeMarketedNCT06972459 | Obesity | Phase 3 | ACTIVE NOT_RECRUITING | 8,741 | Aug 1, 2027 | ||||||
| Retatrutide Small moleculeNCT06859268 | Obesity | Phase 3 | ACTIVE NOT_RECRUITING | 7,605 | Apr 1, 2028 | ||||||
| Retatrutide Small moleculeNCT06260722 | Type 2 Diabetes Mellitus | Phase 3 | ACTIVE NOT_RECRUITING | 1,330 | Feb 1, 2027 | ||||||
| Retatrutide Small moleculeNCT06297603 | Diabetes Type 2 | Phase 3 | ACTIVE NOT_RECRUITING | 2,009 | Nov 1, 2026 | ||||||
| Orforglipron Small moleculeNCT07202884 | Urinary Incontinence,Stress | Phase 3 | RECRUITING | 1,000 | Mar 1, 2028 | ||||||
| Baricitinib Small moleculeNCT07222137 | Diabetes Mellitus, Type 1 | Phase 3 | RECRUITING | 450 | Jul 1, 2031 | ||||||
| Orforglipron Small moleculeNCT07613307 | Diabetes Mellitus, Type 2 | Phase 3 | RECRUITING | 300 | May 1, 2027 | ||||||
| Orforglipron Small moleculeNCT06952530 | Hypertension | Phase 3 | ACTIVE NOT_RECRUITING | 1,948 | Sep 1, 2027 | ||||||
| Orforglipron Small moleculeNCT07223593 | Peripheral Arterial Disease | Phase 3 | RECRUITING | 1,205 | Jun 1, 2028 | ||||||
| Baricitinib Small moleculeNCT04088409 | Uveitis | Phase 3 | ACTIVE NOT_RECRUITING | 30 | Jul 1, 2028 | ||||||
| Orforglipron Small moleculeNCT07241390 | Atherosclerosis Cardiovascular Disease | Phase 3 | RECRUITING | 7,140 | Aug 1, 2031 | ||||||
| Orforglipron Small moleculeMarketedNCT07794579 | Overweight | Phase 3 | RECRUITING | 2,001 | Sep 1, 2030 | ||||||
| Retatrutide Small moleculeNCT06383390 | Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | ACTIVE NOT_RECRUITING | 10,000 | Feb 1, 2029 | ||||||
| Retatrutide Small moleculeNCT06982859 | Diabetes Mellitus | Phase 1 | ACTIVE NOT_RECRUITING | 95 | Jan 1, 2027 | ||||||
| Olomorasib Small moleculeNCT06890598 | Carcinoma, Non-Small-Cell Lung | Phase 3 | RECRUITING | 700 | Feb 1, 2032 | ||||||
| LY3537982 Small moleculeNCT04956640 | Carcinoma, Non-Small-Cell Lung | Phase 3 | ACTIVE NOT_RECRUITING | 1,804 | Apr 1, 2027 | ||||||
| Olomorasib Small moleculeNCT07814417 | Colorectal Neoplasms | Phase 2 | NOT YET_RECRUITING | 50 | Nov 1, 2028 | ||||||
| LY3938577 Small moleculeNCT07215312 | Type 2 Diabetes Mellitus | Phase 2 | ACTIVE NOT_RECRUITING | 166 | Dec 1, 2026 | ||||||
| Lepodisiran RNA therapyNCT06292013 | Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | ACTIVE NOT_RECRUITING | 17,300 | Mar 1, 2029 | ||||||
| Lepodisiran RNA therapyNCT07613294 | Atherosclerosis | Phase 3 | RECRUITING | 252 | Dec 1, 2029 | ||||||
| Eloralintide Small moleculeNCT07369011 | Sleep Apnea, Obstructive | Phase 3 | RECRUITING | 800 | Apr 1, 2028 | ||||||
| Eloralintide Small moleculeNCT07353931 | Osteoarthritis | Phase 3 | RECRUITING | 900 | May 1, 2028 | ||||||
| LY3841136 Small moleculeNCT07401862 | Hepatic Insufficiency | Phase 1 | RECRUITING | 36 | Mar 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every LLY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| olomorasib Breakthrough | KRAS G12C-mutant non-small cell lung cancer | Phase 1/2 | 2026-10-25 | median progression free survival: not reached after nearly 21 months; overall response rate: 62%; median duration of response: 14.5 monthsRead More | New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jonsson PatrikOfficer (EVP & President, LLY Int'l) | Sell | -6,500 54,146.62 held | $1,175.10 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LLY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 5.7 % (32.6 %) | 309.33 M | 257.90 K | 8.91% ( 21.10 K) |
LLY Institutional Ownership Trends
LLY Short Interest
Shares sold short, counted twice a month.
0.83%
Short % of Float
of tradable shares sold short
7.0M
Shares Sold Short
-6.4% vs prior count
2.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LLY ranks across every disease it competes in
Competitive Position is a premium feature
See how LLY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLLY News
LLY▲ +0.7%today
Lilly declares fourth-quarter 2026 dividend
Eli Lilly and Company announced a fourth-quarter 2026 dividend of $1.73 per share. This dividend will be paid on December 10, 2026, to shareholders recorded by November 13, 2026. The announcement highlights Lilly's commitment to returning value to shareholders amidst ongoing advancements in healthcare.
Read more →LLY▲ +0.7%today
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Eli Lilly presented promising data on olomorasib at ESMO 2026, showing durable first-line activity in KRAS G12C-mutant non-small cell lung cancer (NSCLC). The Phase 1/2 LOXO-RAS-20001 trial indicated median progression-free survival had not been reached after nearly 21 months. The ongoing Phase 3 SUNRAY-01 trial is expected to provide further insights in 2027.
Read more →LLY▲ +0.7%today
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Eli Lilly presented Phase 1 data for its investigational ADC, Sofetabart mipitecan (Sofe-M), at ESMO 2026. The combination with bevacizumab showed a 79% confirmed objective response rate and a 100% disease control rate in patients with platinum-sensitive ovarian cancer. The study indicates potential efficacy even in patients previously treated with PARP inhibitors.
Read more →LLYLilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
Eli Lilly has begun construction on a $5 billion manufacturing facility in Richmond, Virginia, which will create 650 high-wage jobs. This site will be the first to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facility. The investment is part of Lilly's broader initiative to expand U.S. manufacturing capabilities.
Read more →LLYLilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
Eli Lilly announced positive one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients with moderately to severely active ulcerative colitis. The study found that 81% of patients responded to treatment, with 50% achieving clinical remission at one year. Lilly plans to submit these findings to regulators for potential label expansion to include pediatric patients.
Read more →LLYLilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Eli Lilly and Company will showcase new data from its oncology pipeline at the 2026 ESMO Congress. Key presentations include Phase 1 data for sofetabart mipitecan in platinum-sensitive ovarian cancer, updated findings for olomorasib in KRAS G12C-mutant lung cancer, and results for Retevmo in RET-mutant medullary thyroid cancer. The data highlight Lilly's commitment to advancing cancer care.
Read more →LLYLilly confirms date and conference call for third-quarter 2026 financial results announcement
Eli Lilly and Company will announce its third-quarter 2026 financial results on October 29, 2026. A conference call will follow at 10 a.m. Eastern time, providing details on the company's financial performance. The call will be accessible via a live webcast, with a replay available afterward.
Read more →LLYNew composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
Eli Lilly's Omvoh (mirikizumab-mrkz) has shown promising results in treating ulcerative colitis and Crohn's disease. In clinical trials, a significant percentage of patients achieved comprehensive disease control and corticosteroid-free deep remission, even those with previous treatment failures. These findings highlight a shift towards more holistic treatment goals in inflammatory bowel disease management.
Read more →LLYNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Eli Lilly presented new data from the TOGETHER-PsO Phase 3b trial, showing that the combination of Taltz and Zepbound leads to broader biomarker changes compared to Taltz alone in patients with psoriasis and obesity. The findings suggest a significant immunometabolic relationship, supporting a more integrated treatment approach. The study highlights the potential for improved patient outcomes in managing both conditions.
Read more →LLYLilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
Eli Lilly will present 21 new data presentations at the Fall Clinical Dermatology Conference 2026, focusing on its dermatology portfolio. Key highlights include findings on EBGLYSS for atopic dermatitis, Taltz and Zepbound for psoriasis and obesity, and long-term outcomes for Olumiant in alopecia areata. The data aims to enhance understanding and treatment of chronic skin conditions.
Read more →LLYLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval for an expanded indication, allowing its use as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without known 17p deletion. This decision is based on the positive results from the BRUIN CLL-313 clinical trial, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval highlights Jaypirca's role in the treatment continuum for CLL/SLL.
Read more →LLYLilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Eli Lilly announced that its oral GLP-1 medication, Foundayo, demonstrated significant reductions in the predicted long-term risks of type 2 diabetes and cardiovascular disease in adults with obesity or overweight. The findings, derived from post-hoc analyses of the ATTAIN-1 trial, suggest that Foundayo could be a valuable treatment option, potentially reducing healthcare costs linked to obesity. The results were published in Diabetes, Obesity and Metabolism.
Read more →LLYLilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Eli Lilly's Phase 3 ACHIEVE-4 trial results for Foundayo (orforglipron) showed it met non-inferiority criteria for major adverse cardiovascular events compared to insulin glargine. The study revealed significant reductions in cardiovascular death and all-cause mortality, alongside improvements in A1C and weight. Foundayo's convenient once-daily dosing may enhance patient adherence.
Read more →LLYNew Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Eli Lilly's EBGLYSS (lebrikizumab-lbkz) has shown promising results in a Phase 3b study for treating moderate-to-severe hand and foot atopic dermatitis. The study reported that over 53% of patients achieved clear or almost clear skin by Week 16, with significant improvements in itch and pain relief. Additionally, nearly 80% of patients expressed satisfaction with their treatment outcomes. These findings will be presented at the EADV Congress.
Read more →LLYLilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Eli Lilly announced positive results from a Phase 2b trial of EloraTZP, a combination of eloralintide and tirzepatide, showing greater weight loss and A1C reduction compared to tirzepatide alone. Participants lost an average of 54.1 lbs and lowered A1C by 2.9% over 48 weeks. Lilly plans to initiate Phase 3 trials by the end of 2026.
Read more →LLYLilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Eli Lilly's TRIUMPH-2 trial results show that retatrutide, a triple hormone receptor agonist, led to significant weight loss and A1C reductions in adults with obesity and type 2 diabetes. Over 80 weeks, participants lost an average of 49.6 lbs, with many no longer classified as obese. The drug also demonstrated improvements in cardiovascular risk factors. Lilly plans to submit a Biologics License Application in early 2027.
Read more →LLYLilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
Eli Lilly's Zepbound (tirzepatide) 10 mg and 15 mg demonstrated greater weight loss compared to Wegovy HD (semaglutide injection 7.2 mg) in a recent analysis. The study, presented at the EASD Annual Meeting, showed that participants on Zepbound 15 mg had over three times the odds of achieving at least a 20% body weight reduction. While the results are promising, some differences in weight loss did not reach statistical significance.
Read more →LLYLilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Eli Lilly announced that Foundayo (orforglipron) 17.2 mg resulted in greater weight loss and A1C reduction compared to oral semaglutide 25 mg in adults with type 2 diabetes. The findings, presented at the EASD Annual Meeting, are based on an indirect comparison using data from the ACHIEVE-3 and PIONEER PLUS studies. This analysis highlights Foundayo's potential as an effective treatment option for managing type 2 diabetes.
Read more →LLYLilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
Eli Lilly has launched the Lilly Change the Course Commitment, aiming to provide equal access to its diabetes and obesity medicines in low- and middle-income countries (LMICs) by 2040. The initiative focuses on registering innovative treatments and strengthening health systems to address significant access gaps. This commitment builds on the success of the previous Lilly 30x30 initiative, which exceeded its target of helping 30 million people by 2025.
Read more →LLYFDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
The FDA has approved Eli Lilly's Olumiant (baricitinib) for pediatric patients aged 12 and older with severe alopecia areata. This decision is based on data from the BRAVE-AA-PEDS study, which demonstrated significant scalp hair regrowth and improved eyebrow and eyelash coverage. The approval provides a much-needed treatment option for adolescents facing the challenges of this chronic condition.
Read more →About Eli Lilly and Company
HeadquartersLILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
BIOPHARMAWATCH ELITE PLUS
Trade the next LLY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime